Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
出版年份 2021 全文链接
标题
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-07-16
DOI
10.1038/s41375-021-01345-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
- (2021) Elise A. Chong et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel
- (2020) Sattva S Neelapu et al. BLOOD
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
- (2020) Kathryn M. Cappell et al. JOURNAL OF CLINICAL ONCOLOGY
- High Rate of Durable Complete Remission in Follicular Lymphoma after CD19 CAR-T cell Immunotherapy
- (2019) Alexandre V. Hirayama et al. BLOOD
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
- (2018) Haneen Shalabi et al. HAEMATOLOGICA
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
- (2018) Haneen Shalabi et al. HAEMATOLOGICA
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma
- (2018) Caron A. Jacobson JOURNAL OF CLINICAL ONCOLOGY
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- New development in CAR-T cell therapy
- (2017) Zhenguang Wang et al. Journal of Hematology & Oncology
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapies for lymphoma
- (2017) Jennifer N. Brudno et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
- (2017) Dina Schneider et al. Journal for ImmunoTherapy of Cancer
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
- (2016) Hanren Dai et al. JNCI-Journal of the National Cancer Institute
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
- (2016) Hanren Dai et al. JNCI-Journal of the National Cancer Institute
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
- (2015) Felicitas Hitz et al. ANNALS OF HEMATOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
- (2014) Laurie H. Sehn et al. BLOOD
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
- (2014) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- (2012) L. H. Sehn et al. BLOOD
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2011) J. W. Friedberg Hematology-American Society of Hematology Education Program
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search